US Edition
Amneal announces proposed refinancing of existing credit agreement
Summary by CDR – Chain Drug Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Amneal announces proposed refinancing of existing credit agreement
BRIDGEWATER, N.J. – Amneal Pharmaceuticals (Amneal) announced that its subsidiary, Amneal Pharmaceuticals LLC (the Issuer), is seeking to borrow $1.800 billion aggregate principal amount of new seven-year term B loans (the new term B loans) under a new term loan facility (the “Term Loan Facility”). The Issuer has also launched an offering of $750 million aggregate principal amount of senior secured notes due 2032 (the notes) in a private offerin…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
